Compare Biogen Inc (BIIB) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PepsiCo, Inc. — how do they compare? Biogen Inc trades at $210.74 (market cap $30.86B), while PepsiCo, Inc. trades at $140.3 (market cap $189.31B). The key difference: PepsiCo, Inc. is far larger — about 6.1× Biogen Inc's market cap, and PepsiCo, Inc. pays a 4.27% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PEP | |
|---|---|---|
Market Cap | $30.86B | $189.31B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $170.44 |
52-Week Low | $132.22 | $134.95 |
Enterprise Value | $37.93B | $231.81B |
Dividend Yield | — | 4.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
PepsiCo (PEP) trades at $140.22, up 1.3% on the day, with a bearish technical signal but strong fundamentals including a 10.78% net margin and consistent earnings beats. Recent news highlights price cuts on snacks to address consumer pushback, while analysts project a $158.79 price target. Cash flow trends show improved net cash generation in 2025.
The outlook is mixed: valuation metrics like P/E of 18.18 are reasonable, and dividend yield near 4% offers income, but risks include competitive pressures and volatile cash flows. Wall Street sentiment is cautious with 64% hold ratings, suggesting patience for turnaround execution amid price sensitivity concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
